Last reviewed · How we verify
batch 2 of Ad5-nCoV
batch 2 of Ad5-nCoV is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently FDA-approved. Also known as: Convidecia.
At a glance
| Generic name | batch 2 of Ad5-nCoV |
|---|---|
| Also known as | Convidecia |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- batch 2 of Ad5-nCoV CI brief — competitive landscape report
- batch 2 of Ad5-nCoV updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about batch 2 of Ad5-nCoV
What is batch 2 of Ad5-nCoV?
batch 2 of Ad5-nCoV is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention.
Who makes batch 2 of Ad5-nCoV?
batch 2 of Ad5-nCoV is developed and marketed by Jiangsu Province Centers for Disease Control and Prevention (see full Jiangsu Province Centers for Disease Control and Prevention pipeline at /company/jiangsu-province-centers-for-disease-control-and-prevention).
Is batch 2 of Ad5-nCoV also known as anything else?
batch 2 of Ad5-nCoV is also known as Convidecia.
What development phase is batch 2 of Ad5-nCoV in?
batch 2 of Ad5-nCoV is FDA-approved (marketed).
Related
- Manufacturer: Jiangsu Province Centers for Disease Control and Prevention — full pipeline
- Also known as: Convidecia
- Compare: batch 2 of Ad5-nCoV vs similar drugs
- Pricing: batch 2 of Ad5-nCoV cost, discount & access